Armata Gains FDA Fast Track for AP-SA02 Therapy
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
antibiotic resistance
Advertisement
Talicia U.S. Commercialization Launch Expands Reach
February 25, 2026 – Raleigh, North Carolina & Tel-Aviv, Israel RedHill Biopharma Ltd. has announced the full operational and...
Positive Zoliflodacin Phase 3 Data Published in The Lancet
LONDON, December 12, 2025 — Innoviva Specialty Therapeutics announced the publication of positive Phase 3 clinical results for zoliflodacin...
Armata Pharmaceuticals Launches Advanced cGMP Phage Plant
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Advertisements
Glycovax Pharma to Develop Pseudomonas Vaccine After NRC License Approval
MONTREAL, Aug. 18, 2025 — Glycovax Pharma has secured a license from the National Research Council of Canada (NRC)...
Advertisement
